D.E. Shaw & Co
NUVB icon

D.E. Shaw & Co’s Nuvation Bio NUVB Stock Holding History

D.E. Shaw & Co’s Portfolio NUVB Stock Details NUVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.48M Buy
1,140,000
+747,014
+190% +$3.65M ﹤0.01% 2192
2026
Q1 		$1.69M Sell
392,986
-482,816
-55% -$2.69M ﹤0.01% 3044
2025
Q4 		$7.85M Buy
+875,802
New +$5.43M ﹤0.01% 1957
2025
Q2 		– Sell
-12,100
Closed -$21.3K – 4602
2025
Q1 		$21.3K Sell
12,100
-35,300
-74% -$80.4K ﹤0.01% 4103
2024
Q4 		$126K Sell
47,400
-63,827
-57% -$164K ﹤0.01% 4144
2024
Q3 		$255K Sell
111,227
-60,568
-35% -$185K ﹤0.01% 4057
2024
Q2 		$502K Sell
171,795
-689,145
-80% -$2.1M ﹤0.01% 3622
2024
Q1 		$3.13M Buy
860,940
+346,010
+67% +$664K ﹤0.01% 2267
2023
Q4 		$778K Buy
514,930
+446,959
+658% +$575K ﹤0.01% 3296
2023
Q3 		$91.1K Sell
67,971
-44,265
-39% -$73.7K ﹤0.01% 3864
2023
Q2 		$202K Buy
112,236
+32,535
+41% +$55.3K ﹤0.01% 3735
2023
Q1 		$132K Sell
79,701
-38,570
-33% -$78.2K ﹤0.01% 3958
2022
Q4 		$227K Sell
118,271
-100,554
-46% -$203K ﹤0.01% 4198
2022
Q3 		$490K Buy
218,825
+71,110
+48% +$203K ﹤0.01% 4056
2022
Q2 		$479K Buy
147,715
+114,937
+351% +$501K ﹤0.01% 4113
2022
Q1 		$172K Sell
32,778
-37,192
-53% -$209K ﹤0.01% 4906
2021
Q4 		$595K Sell
69,970
-95,521
-58% -$878K ﹤0.01% 4303
2021
Q3 		$1.65M Sell
165,491
-3,424
-2% -$31K ﹤0.01% 3198
2021
Q2 		$1.57M Buy
+168,915
New +$1.93M ﹤0.01% 3171
2021
Q1 		– Sell
-115,700
Closed -$1.35M – 4349
2020
Q4 		$1.35M Buy
+115,700
New +$1.2M ﹤0.01% 2823

Other funds holding NUVB

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
DFO
Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

D.E. Shaw & Co's NUVB Position: Q2 2026 in Review

D.E. Shaw & Co increased its Nuvation Bio (NUVB) stake by 190% in Q2 2026, buying an estimated $3.65M and bringing the position to 1,140,000 shares worth $6.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2192.

D.E. Shaw & Co first reported a position in NUVB in Q4 2020 and has held it in 20 quarters since. The position peaked at $7.85M in Q4 2025. 244 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

  • D.E. Shaw & Co held 1,140,000 shares of Nuvation Bio worth $6.48M as of Q2 2026.
  • D.E. Shaw & Co bought 747,014 Nuvation Bio shares in Q2 2026, an estimated $3.65M.
  • Nuvation Bio made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #2192 holding.
  • D.E. Shaw & Co first reported a position in Nuvation Bio in Q4 2020 and has held it in 20 quarters since.
  • D.E. Shaw & Co's Nuvation Bio position peaked at $7.85M in Q4 2025.
  • 244 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.